Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats

Journal of Neuroscience Research

Volumn 90, Issue 7, 2012, Pages 1474-1479

  Romero, Thiago R L ^a   Galdino, Giovane S ^a   Silva, Grazielle C ^a   Resende, Lívia C ^a   Perez, Andréa C ^a   Cortes, Steyner F ^a   Duarte, Igor D G ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

N palmitoyl ethanolamine (PEA); Neuronal NO synthase, NO cyclic GMP pathway; Peripheral antinociception

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ANTINOCICEPTIVE AGENT; ARGININE; CYCLIC GMP; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; N PALMITOYL ETHANOLAMINE; N(G) NITROARGININE; N(W) PROPYLARGININE; N5 (1 IMINOETHYL)ORNITHINE DIHYDROCHLORIDE; N6 (1 IMINOETHYL)LYSINE HYDROCHLORIDE; NITRIC OXIDE; NITRITE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COLORIMETRY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; ENDOTHELIUM; ENZYME RELEASE; HYPERALGESIA; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALGESICS; ANIMALS; ARGININE; CYCLIC GMP; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ETHANOLAMINES; HYPERALGESIA; MALE; NEURAL INHIBITION; NEURAL PATHWAYS; NITRIC OXIDE; NOCICEPTION; PALMITIC ACIDS; RATS; RATS, WISTAR;

EID: 84860920579     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22797     Document Type: Article

References (34)

1. + channels activation. Life Sci 74: 2577-2591.
2. Calignano A, La Rana G, Giuffrida A, Piomelli D. 1998. Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
3. Chaitoff KA, Patel D, Ally A. 2008. Effects of endothelial NOS antagonism within the periaqueductal gray on cardiovascular responses and neurotransmission during mechanical, heat, and cold nociception. Brain Res 1236: 93-104.
4. 1, TRPV1 and PPARgamma receptors and neurotrophic factors. Pain 139: 541-550.
5. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, Sorrentini I, Di Marzo V. 2005. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154-1163.
6. De Filippis D, D'Amico A, Cinelli MP, Esposito G, Di Marzo V, Iuvone T. 2008. Adelmidrol, a palmitoylethanolamide analog, reduces chronic inflammation in a carrageenin-granuloma model in rats. J Cell Mol Med 13: 1086-1095.
7. Di Marzo V, Fontana A. 1995. Anandamide, an endogenous cannabinomimetic eicosanoid: "killing two birds with one stone." Prostagland Leukot Essent Fatty Acids 53: 1-11.
8. Duarte IDG, Ferreira SH. 1992. The molecular mechanism of central analgesia induced by morphine or carbachol and the L-arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 321: 171-174.
9. Duarte IDG, Lorenzetti BB, Ferreira SH. 1990. Acetylcholine induces peripheral analgesia by the release of nitric oxide. Eur J Pharmacol 186: 289-293.
10. Duarte IDG, Dos Santos IR, Lorenzetti BB, Ferreira SH. 1992. Analgesia by direct antagonism of nociceptor sensitization involves the L-arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 217: 225-227.
11. Green AF, Young PA. 1951. A comparison of heat and pressure analgesiometric methods in rats. Br J Pharmacol 6: 572-585.
12. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. 1982. Analysis of nitrate, nitrite and [′5N]nitrate in biological fluids. Anal Biochem 126: 131-138.
13. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. 2003. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73: 2345-2353.
14. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
15. Knowles RG, Palacios M, Palmer RMJ, Moncada S. 1989. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A 86: 5159-5162.
16. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. 2006. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319: 1051-1061.
17. Moncada S, Radomski MW, Palmer RM. 1988. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 37: 2495-2501.
18. Moncada S, Palmer RMJ, Higgs EA. 1991. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-142.
19. Morisset V, Ahluwalia J, Nagy I, Urban L. 2001. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur J Pharmacol 429: 93-100.
20. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
21. Papadopolou S, Hartmann P, Lips KS, Kummer W, Haberberger RV. 2004. Nicotinic receptor mediated stimulation of NO-generation in neurons of rat thoracic dorsal root ganglia. Neurosci Lett 361: 32-35.
22. Peana AT, Marzocco S, Popolo A, Pinto A. 2006. (-)-Linalool inhibits in vitro NO formation: Probable involvement in the antinociceptive activity of this monoterpene compound. Life Sci 78: 719-723.
23. Randall LO, Sellito JJ. 1957. A method for measurement of analgesic activity on inflamed tissues. Arch Int Pharmacodyn 111: 409-419.
24. Re G, Barbero R, Miolo A, Di Marzo V. 2007. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J 173: 21-30.
25. Reis GM, Pacheco D, Perez AC, Klein A, Ramos MA, Duarte ID. 2009. Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci 85: 351-356.
26. Reutov VP, Sorokina EG. 1998. NO-synthase and nitrite-reductase components of nitric oxide cycle. Biochemistry (Moscow) 63: 874-884.
27. 2 Adrenoceptor agonist xylazine induces peripheral antinociceptive effect by activation of the L-arginine/nitric oxide/cyclic GMP pathway in rat. Eur J Pharmacol 613: 64-67.
28. Romero-Sandoval A, Eisenach JC. 2007. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106: 787-794.
29. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. 2002. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277: 3310-3317.
30. Schwartz SE, White WH. 1983. In: Trace atmospheric constituents: properties, transformation and fates. New York: John Wiley & Sons. p 1-117.
31. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. 1994. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 74: 349-353.
32. Stefano GB, Rialas CM, Deutsch DG, Salzet M. 1998. Anandamide amidase inhibition enhances anandamide-stimulated nitric oxide release in invertebrate neural tissues. Brain Res 793: 341-345.
33. Welch SP, Thomas C, Patrick GS. 1995. Modulation of cannabinoid-induced antinociception after intracerebroventricular vs. intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272: 310-321.
34. 2 reaction. Chem Res Toxicol 6: 23-27.